Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

143.18 +2.47 (+1.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

US Stocks Mixed; JM Smucker Slashes Annual Guidance ↗

August 28, 2024

Via Benzinga

Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗

August 28, 2024

As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.

Via Investor's Business Daily

Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗

August 27, 2024

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.

Via Benzinga

Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). ↗

August 22, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing?

Via Chartmill

Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts ↗

August 19, 2024

Via Benzinga

NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

August 19, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.

Via Chartmill

NASDAQ:NBIX is not too expensive for the growth it is showing. ↗

August 19, 2024

Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences ↗

August 01, 2024

Via Benzinga

NASDAQ:NBIX, a strong growth stock, setting up for a breakout. ↗

July 26, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.

Via Chartmill

9 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2024

Via Benzinga

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

So Much For Expecting The Fed To Stick The Landing ↗

August 04, 2024

Now is not the time to be fully invested.

Via Talk Markets

Topics Economy

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗

August 02, 2024

Apple and Meta had strong results, while AI spending remains robust.

Via Investor's Business Daily

Topics Artificial Intelligence

NASDAQ:NBIX, a growth stock which is not overvalued. ↗

July 26, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

Via Chartmill

Should Quality Investors Include NASDAQ:NBIX in Their Portfolio? ↗

July 25, 2024

Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.

Via Chartmill

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences ↗

July 10, 2024

Via Benzinga

Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

July 05, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout.

Via Chartmill

NASDAQ:NBIX is not too expensive for the growth it is showing. ↗

July 05, 2024

Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors. ↗

July 04, 2024

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock.

Via Chartmill

Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued. ↗

June 20, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals.

Via Chartmill

Key Takeaways From Neurocrine Biosciences Analyst Ratings ↗

May 28, 2024

Via Benzinga

Exploring NASDAQ:NBIX's quality characteristics. ↗

May 27, 2024

Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

May 24, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating.

Via Chartmill

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗

June 17, 2024

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

Via InvestorPlace

Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? ↗

June 14, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗

June 14, 2024

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

Via Investor's Business Daily

Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. ↗

June 13, 2024

Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced.

Via Chartmill

In the world of growth stocks, NASDAQ:NBIX shines as a value proposition. ↗

May 23, 2024

Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam ↗

May 04, 2024

The market rally appears to be picking up steam.

Via Investor's Business Daily

A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation ↗

May 03, 2024

Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.